Chronic obstructive pulmonary disease

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals

July 28, 2025

0 1

GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a…